Literature DB >> 12825970

Use of herbal medicines by patients receiving warfarin.

Raymond S M Wong1, Gregory Cheng, Thomas Y K Chan.   

Abstract

BACKGROUND: Patients receiving warfarin therapy are discouraged from taking herbal medicines. Whether patients adhere to this advice and, if they do not, the types of products they use, are not known.
OBJECTIVE: The objective of this observational study was to estimate the magnitude of use of herbal medicines among Chinese patients attending the Warfarin Clinic of the Prince of Wales Hospital in Hong Kong.
METHODS: A medical officer interviewed all patients who attended the Warfarin Clinic during May 2001. Patients were asked about the use of herbal medicines in the preceding week. Demographic data, indication and duration of warfarin therapy, and International Normalised Ratio (INR) value at the time of the visit were also noted.
RESULTS: Of 107 patients interviewed, 28 (26%) claimed to have taken herbal medicines during the week prior to the clinic visit. The users of herbal medicines had lower INR values than non-users (mean INR value 2.41 +/- 0.65 vs 2.75 +/- 0.65, p = 0.019), possibly because of a lower warfarin dosage (mean dosage 2.93 mg/day +/- 1.23 vs 3.34 mg/day +/- 1.45; p = 0.185) and because a smaller proportion of such patients had heart valve replacement (21% vs 39%, p = 0.141). 'Herbal soup' (soup made at home from vegetables, meat and certain herbs for consumption with the main meals) and 'cool tea' (herbal decoction for the treatment of 'endogenous heat') were the most popular and were taken by 12 (11%) and 11 (10%) patients, respectively. Four patients took proprietary medicines each containing between one and three different herbs that could potentially enhance or antagonise the effects of warfarin. None of the patients in this study showed any evidence of thromboembolism or bleeding on the day of clinic visit.
CONCLUSION: Among Chinese patients treated with warfarin at a Hong Kong clinic, the use of herbal medicines was relatively common. Healthcare professionals play an important role in educating the patients and updating the list of herbal medicines that should be avoided by patients taking warfarin.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12825970     DOI: 10.2165/00002018-200326080-00004

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  6 in total

Review 1.  Interaction between warfarin and danshen (Salvia miltiorrhiza).

Authors:  T Y Chan
Journal:  Ann Pharmacother       Date:  2001-04       Impact factor: 3.154

2.  Factors determining the maintenance dose of warfarin in Chinese patients.

Authors:  H C Yu; T Y Chan; J A Critchley; K S Woo
Journal:  QJM       Date:  1996-02

Review 3.  The international normalized ratio. A guide to understanding and correcting its problems.

Authors:  J Hirsh; L Poller
Journal:  Arch Intern Med       Date:  1994-02-14

Review 4.  Herb-drug interactions.

Authors:  A Fugh-Berman
Journal:  Lancet       Date:  2000-01-08       Impact factor: 79.321

Review 5.  Monitoring the safety of herbal medicines.

Authors:  T Y Chan
Journal:  Drug Saf       Date:  1997-10       Impact factor: 5.606

6.  Relationship between patients' warfarin knowledge and anticoagulation control.

Authors:  Elaine Othilia Y L Tang; Cemen S M Lai; Kenneth K C Lee; Raymond S M Wong; Gregory Cheng; Thomas Y K Chan
Journal:  Ann Pharmacother       Date:  2003-01       Impact factor: 3.154

  6 in total
  15 in total

Review 1.  Views on traditional Chinese medicine amongst Chinese population: a systematic review of qualitative and quantitative studies.

Authors:  Vincent C H Chung; Polly H X Ma; Chun Hong Lau; Samuel Y S Wong; Eng Kiong Yeoh; Sian M Griffiths
Journal:  Health Expect       Date:  2012-05-31       Impact factor: 3.377

2.  An instrument to evaluate pharmacists' patient counseling on herbal and dietary supplements.

Authors:  Hsiang-Wen Lin; A Simon Pickard; Gail B Mahady; George Karabatsos; Stephanie Y Crawford; Nicholas G Popovich
Journal:  Am J Pharm Educ       Date:  2010-12-15       Impact factor: 2.047

Review 3.  Interaction between warfarin and Chinese herbal medicines.

Authors:  Yan Ting Chua; Xiang Ling Ang; Xi Ming Zhong; Kei Siong Khoo
Journal:  Singapore Med J       Date:  2015-01       Impact factor: 1.858

4.  Factors affecting the maintenance stable warfarin dosage in Hong Kong Chinese patients.

Authors:  Vivian W Y Lee; Joyce H S You; Kenneth K C Lee; T S Chau; Mary M Y Waye; Gregory Cheng
Journal:  J Thromb Thrombolysis       Date:  2005-08       Impact factor: 2.300

5.  Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation?

Authors:  J H S You; F W H Chan; R S M Wong; G Cheng
Journal:  Br J Clin Pharmacol       Date:  2005-05       Impact factor: 4.335

6.  The effects of ferulic acid on the pharmacokinetics of warfarin in rats after biliary drainage.

Authors:  Haigang Li; Yang Wang; Rong Fan; Huiying Lv; Hua Sun; Haitang Xie; Tao Tang; Jiekun Luo; Zian Xia
Journal:  Drug Des Devel Ther       Date:  2016-07-06       Impact factor: 4.162

7.  Effect of race/ethnicity on the efficacy of warfarin: potential implications for prevention of stroke in patients with atrial fibrillation.

Authors:  Albert Yuh-Jer Shen; Wansu Chen; Janis F Yao; Somjot S Brar; Xunzhang Wang; Alan S Go
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 8.  Dietary supplements, herbs and oral anticoagulants: the nature of the evidence.

Authors:  Ann K Wittkowsky
Journal:  J Thromb Thrombolysis       Date:  2007-09-29       Impact factor: 2.300

Review 9.  The use of complementary and alternative medicine by people with cardiovascular disease: a systematic review.

Authors:  Suzanne J Grant; Yu Sun Bin; Hosen Kiat; Dennis Hsu-Tung Chang
Journal:  BMC Public Health       Date:  2012-04-26       Impact factor: 3.295

10.  Prevalence of dietary supplement use in patients with proven or suspected cardiovascular disease.

Authors:  Yu Sun Bin; Hosen Kiat
Journal:  Evid Based Complement Alternat Med       Date:  2010-10-13       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.